Article Sidebar

PDF
Issue: Vol. 561 No. 3 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v561i3.18594
Date Published: 11/08/2026
Views 28
Downloads 31
How to Cite
Lê, T. T. V., Nguyễn, B. H., & Nguyễn, M. H. (2026). ASSESSING THE OUTCOMES OF CERVICAL CANCER SCREENING USING CERVICAL CYTOLOGY, HPV DNA, AND E6/E7 mARN TESTING. Vietnam Medical Journal, 561(3). https://doi.org/10.51298/vmj.v561i3.18594

ASSESSING THE OUTCOMES OF CERVICAL CANCER SCREENING USING CERVICAL CYTOLOGY, HPV DNA, AND E6/E7 mARN TESTING

Thị Thanh Vân Lê1, , Bích Hồng Nguyễn2, Mạnh Hùng Nguyễn3
1 Bệnh viện Quốc tế Mặt Trờ
2 Trường Đại học Điều dưỡng Nam Định
3 Bệnh viện Quốc tế Mặt Trời

Main Article Content

Abstract

Objective: To assess cervical cancer screening outcomes utilizing HPV DNA, E6/E7 mRNA testing, and cervical cytology (Thin Prep).

Subjects and methods: From January 1, 2025, to December 31, 2025, 132 women who visited Sun Group International Hospital for cervical cancer screening underwent cervical cytology (Thin Prep), HPV DNA, and E6/E7 mRNA testing as part of a cross-sectional descriptive study.

Results: 19.7% of cases had abnormal cytology results, with 3% having high-grade squamous cell carcinoma (HSIL) and 6.1% having low-grade squamous cell carcinoma (LSIL). 3.8% of the 13.6% of cases that tested positive for HPV DNA had low-risk HPV types, 6.8% had high-risk HPV types, and 3% had two HPV types. In 16 of the 132 cases, the E6/E7 mRNA gene was expressed. In individuals with HSIL cytology, the E6/E7 mRNA test positivity rate was 75% (p < 0.05).

Conclusion: The hospital’s HPV-positive rate was 13.6%, and the E6/E7 mRNA gene was expressed in 12.1% of patients. As cervical cytology abnormalities increased, so did the positive rate for E6/E7 mRNA (p < 0.05).

Keywords

HPV DNA, E6/E7 mRNA, cervical cytology, and cervical cancer

Article Details

References

1. Li Y, Wu X. Evaluating HPV E6/E7 mRNA expression and genotype prevalence in cervical cytology and biopsy samples from Yunnan Province, China. ecancermedicalscience. 2025;19:1893.
2. Huy HQ, Hoài PM, Linh HH, Hồng NT, Thủy NT. Đặc điểm lâm sàng, cận lâm sàng và kết quả sàng lọc ung thư cổ tử cung tại khoa Sản Bệnh viện Trường Đại học Y Dược Thái Nguyên. Tạp chí Y học Việt Nam. 2023;527(1B).
3. Trương QV, Cao NT. Nghiên cứu đặc điểm lâm sàng và cận lâm sàng ở các phụ nữ có tổn thương tiền ung thư và ung thư cổ tử cung. Tạp chí Phụ sản. 2010;8(4):60-68.
4. DeMay MR. An overview of Bethesda System. In: The Pap Test: Exfoliative Gynecologic Cytology. Chicago: ASCP Press; 2005. p. 235-244.
5. Sherman EM, Abdul-Karim WF, Berek SJ, et al. Atypical Squamous Cells. In: Solomon D, Nayar R, editors. The Bethesda System for Reporting Cervical Cytology. Chicago: Springer; 2004. p. 67-89.
6. Trần TTT, Lê VQ. Tỷ lệ nhiễm HPV và mối liên quan đến các bất thường tế bào cổ tử cung ở bệnh nhân khám phụ khoa tại Bệnh viện K. Tạp chí Y học Việt Nam. 2021;509(1).
7. Alacam S, Bakir A. Human Papillomavirus Prevalence and Genotype Distribution in Cervical Swab Samples in Istanbul, Turkey. J Infect Dev Ctries. 2021;15(8):1190-1196.
8. Zhuang L, Jiang S, Zhao J, et al. Performance of the Human Papillomavirus E6/E7 mRNA Assay in the Primary Screening of Cervical Cancer: Opportunistic Screening in Fujian, China. Int J Womens Health. 2022;14:1519-1530.
9. Park IU, Wojtal N, Silverberg MJ, et al. Cytology and human papillomavirus cotest results preceding incident high-grade cervical intraepithelial neoplasia. PLoS One. 2015;10(3):e0118938.
10. Derbie A, et al. HPV E6 and E7 mRNA Test for the Detection of High-Grade Cervical Lesions. JAMA Netw Open. 2025;8(2):e245678.